Obese Patients With or Without Comorbidities (RIO-North America)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00029861
Recruitment Status : Completed
First Posted : January 24, 2002
Last Update Posted : April 20, 2009
Information provided by:

Brief Summary:
To assess the effects of weight loss and weight maintenance over a period of two years when prescribed with a hypocaloric diet in obese patients with or without comorbidities

Condition or disease Intervention/treatment Phase
Obesity Weight Loss Drug: Rimonabant (SR141716) Phase 3

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3045 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Prevention
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study of Weight-Reducing and Prevention of Weight Regain Effects and Safety in Obese Patients With or Without Comorbidities
Study Start Date : August 2001
Actual Primary Completion Date : April 2004
Actual Study Completion Date : April 2004

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. Change in body weight

Secondary Outcome Measures :
  1. Metabolic parameters

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
  • Stable weight (variation of less than 5 kg within 3 months prior to screening visit)
  • BMI (Body Mass Index) of 30 or greater in patients with or without comorbidities, or BMI greater than 27 in patients with treated or untreated hypertension and/or treated or untreated dyslipidemia

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00029861

  Hide Study Locations
United States, Alabama
Radiant Research
Birmingham, Alabama, United States, 35209
United States, Arizona
Radiant Research
Phoenix, Arizona, United States, 85013
United States, California
East Bay Clinical Trial Center
Concord, California, United States, 94520
Feighner Research Institute
San Diego, California, United States, 92121
Scripps Clinic
San Diego, California, United States, 92130
Diablo Clinical Research, Inc.
Walnut Creek, California, United States, 94598
United States, Colorado
Ranch View Family Medicine
Highlands Ranch, Colorado, United States, 80130
Longmont Medical Research Network
Longmont, Colorado, United States, 80501
United States, Delaware
Health Core, Inc.
Newark, Delaware, United States, 19713
United States, District of Columbia
George Washington Univ. Wieght Mmgt Program
Washington, District of Columbia, United States, 20037
United States, Florida
Miami Research Associates
Miami, Florida, United States, 33173
Anchor Research Center
Naples, Florida, United States, 34102
Central Florida Clinical Solutions
Ocoee, Florida, United States, 34761
Orlando Clinical Research Center
Orlando, Florida, United States, 32806
Palm Beach Research Center
West Palm Beach, Florida, United States, 33409
United States, Georgia
Medical Dietetics, Inc.
Atlanta, Georgia, United States, 30339
United States, Illinois
Springfield Diabetes and Endocrine Center
Springfield, Illinois, United States, 62704
United States, Indiana
Medical Research Consortium
Indianapolis, Indiana, United States, 46208
United States, Kansas
Wichita Clinic, PA
Wichita, Kansas, United States, 67208
United States, Kentucky
University of KY Internal Medicine
Lexington, Kentucky, United States, 40536-9841
United States, Louisiana
Pennington Center
Baton Rouge, Louisiana, United States, 70808
United States, Massachusetts
JM Clinical Trials, Inc.
Swansea, Massachusetts, United States, 02777
United States, Montana
Montana Medical Research, LLC
Missoula, Montana, United States, 59804
United States, New Hampshire
Endocrinology and Diabetes Consultants, PC
Dover, New Hampshire, United States, 03820
United States, New Jersey
Radiant Research
Lawrenceville, New Jersey, United States, 08648
United States, New Mexico
Lovelace Scientific Resources
Albuquerque, New Mexico, United States, 87108
United States, New York
Central New York Clinical Research
Manlius, New York, United States, 13104
Comprehensive Weight Control Program
New York, New York, United States, 10021
St. Luke's Roosevelt Hospital Center
New York, New York, United States, 10025
United States, North Carolina
Center for Nutrition and Preventive Medicine
Charlotte, North Carolina, United States, 28207
Multi-Specialty Research Associates of North Carolina
Raleigh, North Carolina, United States, 27609
United States, Ohio
South Dayton Research Associates
Beavercreek, Ohio, United States, 45431
Lindner Clinical Trials Center
Cincinnati, Ohio, United States, 45219
Radiant Research
Columbus, Ohio, United States, 43212
United States, Oregon
Radiant Research
Portland, Oregon, United States, 97201
United States, Pennsylvania
SFM Clinical Trials
Scotland, Pennsylvania, United States, 17254
Radiant Research
Wyomissing, Pennsylvania, United States, 19610
United States, Tennessee
Chattanooga, Tennessee, United States, 37404
Clinical Research Associates, Inc
Nashville, Tennessee, United States, 37203
United States, Texas
Radiant Research
Austin, Texas, United States, 78758
Dallas Diabetes and Endocrine Center
Dallas, Texas, United States, 75230
nTouch Research
Houston, Texas, United States, 77024
Quality Research, Inc.
San Antonio, Texas, United States, 78209
United States, Utah
Advanced Clinical Research
Salt Lake City, Utah, United States, 84102
United States, Virginia
Commonwealth Clinical Research Specialists (CCRS)
Richmond, Virginia, United States, 23226
United States, Washington
Rainer Clinical Research Center, Inc.
Renton, Washington, United States, 98055-5704
United States, Wisconsin
Clinical Nutrition Clinic, University of Wisconsin
Madison, Wisconsin, United States, 53705
Canada, Ontario
Corunna Medical Clinic
Corunna, Ontario, Canada, N0N1G0
Quarry Family Medicine Clinic
Kingston, Ontario, Canada, K7L3E4
Trial Management Group
Richmond Hill, Ontario, Canada, L4E3S8
Group North
Windsor, Ontario, Canada, N8X3V6
Sponsors and Collaborators
Study Director: ICD CSD Sanofi

Publications of Results:
Responsible Party: ICD Study Director, sanofi-aventis Identifier: NCT00029861     History of Changes
Other Study ID Numbers: EFC4743
First Posted: January 24, 2002    Key Record Dates
Last Update Posted: April 20, 2009
Last Verified: April 2009

Keywords provided by Sanofi:
Weight Loss
Weight Reduction

Additional relevant MeSH terms:
Body Weight
Weight Loss
Signs and Symptoms
Body Weight Changes
Cannabinoid Receptor Antagonists
Cannabinoid Receptor Modulators
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs